TY - JOUR T1 - EPV226/#634 Hyperthermic intraperitoneal chemotherapy with CO2 recirculation system (PRS) after interval debulking surgery in advanced ovarian cancer (AOC): preliminary efficacy results from a phase II study JF - International Journal of Gynecologic Cancer JO - Int J Gynecol Cancer SP - A118 LP - A119 DO - 10.1136/ijgc-2021-IGCS.297 VL - 31 IS - Suppl 4 AU - F Murgia AU - V Carone AU - L Leone AU - V Caroli Casavola AU - A Cristofano AU - A Milano AU - V Delmonte AU - G Surico AU - F Legge Y1 - 2021/11/01 UR - http://ijgc.bmj.com/content/31/Suppl_4/A118.3.abstract N2 - Objectives The addition of HIPEC to IDS in AOC has recently showed advantages in prolonging both disease-free and overall survival in AOC patients responding to neoadjuvant chemotherapy. We investigated the pattern of recurrence in a preliminary series of AOC patients treated by HIPEC with a new CO2 PRS after IDS.Methods Twenty patients were prospectively enrolled during the study period. All patients underwent 3 cycles of neoadjuvant chemotherapy with carboplatin AUC5 + paclitaxel 175 mg/m2 and achieved complete cytoreduction at the time of IDS. HIPEC with cisplatin (75 mg/m2, temperature 42°C, for 60 minutes) was administered with a closed CO2 PRS.Results Seven out of twenty (35%) patients underwent ultraradical surgical procedures and 3 (15%) bowel resection. After a median follow-up of 21 months (range 7–28) we registered 9 recurrences with a median time-to-recurrence of 9 months (range 5–21). Interestingly 7/9 (77.8%) recurrences were nodal while only one patient had peritoneal relapse (5%) and one more recurred with pleural disease. Only 2 patients died from relapsed disease.Conclusions Our preliminary efficacy data showed that peritoneal recurrence in AOC may be potentially reduced by the implementation of HIPEC with the CO2 PRS, probably due to a better drug distribution in the peritoneal cavity. This is of critical importance given that pattern of recurrence as carcinomatosis is undoubdtely associated with unfavourable outcome. ER -